Seattle Genetics is a biotechnology company founded in 1998 by Clay Siegall. This company was established with the aim of coming up with a product pipeline that satisfied unmet medical needs. Seattle Genetics has since become an industry leader in the development of antibody- drug conjugates (ADCs), a technology that is designed to harness the power of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
Dr. Clay Siegall, the founder, Chief Executive Officer, President and Chairman of the Board of Seattle Genetics brings a wealth of experience to this industry. He has a Ph.D. in Genetics from George Washington University. Previously, He worked at the National Cancer Institute and the National Health Institute between 1988 and 1991. He then went on to Bristol-Myers Squibb Pharmaceutical Research Institute, where he worked from 1991-1997. When Bristol-Myers decided to close its operations in Seattle, he went on to form Seattle Genetics based on the passion he had for making cancer treatment available and affordable to all.
It is during Dr. Siegall’s tenure at Seattle Genetics that the company has built a portfolio of antibody-based cancer therapies. The most well known of these is ADCETRIS (brentuximab vedotin), was granted approval by the United States Food and Drug Administration in 2001. This drug is currently available in 65 countries. Clay Siegall has also been instrumental in fundraising activities, having secured over $330 million through private and public financing. He has also secured strategic ADC collaborations with other companies like Genentech, Bayer, and Progenics among others, which have generated at least $65 million since 2001.
Dr. Clay Siegall’s dedication to the treatment and possible cure of cancer and other life-threatening illnesses using ADC therapy is a challenge to all of us. He has made this his life’s purpose. He has written over 70 publications and holds over 15 patents, all of which prove that he has a lot more in store for the medical world. Clay Siegall’s expertise in this field has led to his being invited to sit on the Boards of other companies, including Alder Biopharmaceuticals, Mirna Therapeutics, and Ultragenyx. Based on what he has achieved so far at Seattle Genetics, it is clear that Dr. Siegall is a man to watch in the field of genetics and ADC therapy.